SCHEMBL1286718

SCHEMBL1286718

O=C(NCC1CC=NCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 7/20 0.50
▸ CCNA2 P20248 6/20 0.50
▸ CDK1 P06493 5/20 0.37
▸ CCNB1 P14635 5/20 0.37
▸ CCNA1 P78396 1/20 0.37
▸ ADORA2A P29274 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ GSK3B P49841 6/20 0.36
▸ KCNH2 Q12809 6/20 0.36
▸ CHRM1 P11229 2/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ BCL3 P20749 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ LYN P07948 1/20 0.34
▸ GRK2 P25098 1/20 0.34
▸ CLK1 P49759 1/20 0.34
▸ GSK3A P49840 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8219161 0.88 CCNA2 (0.63) CDK2CCNA2CDK1CCNB1CCNA1
SCHEMBL8261337 0.85 CCNA2 (0.57) CDK2CCNA2CDK1CCNB1ADORA2A
SCHEMBL8219257 0.84 CDK2 (0.56) CDK2CCNA2CDK1CCNB1CCNA1
SCHEMBL8228035 0.83 CCNA2 (0.55) CDK2CCNA2ADORA2AADORA1GSK3B
SCHEMBL8226199 0.82 CCNA2 (0.53) CDK2CCNA2CDK1CCNB1ADORA2A
SCHEMBL8262274 0.81 CDK2 (0.50) CDK2CCNA2CDK1CCNB1CCNA1
SCHEMBL8219744 0.81 CDK2 (0.50) CDK2CCNA2CDK1CCNB1CCNA1
SCHEMBL8228006 0.80 CDK2 (0.49) CDK2CCNA2CDK1CCNB1CCNA1
SCHEMBL13543788 0.79 CCNA2 (0.48) CDK2CCNA2CDK1CCNB1ADORA2A
SCHEMBL8261195 0.78 GSK3B (0.53) CDK2CCNA2GSK3BKCNH2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651612-B1 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS ASTEX THERAPEUTICS LTD (GB) 2012-04-11 — — EP disclosed
WO-2008007122-A2 COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S ASTEX THERAPEUTICS LIMITED (GB) 2008-01-17 — — WO disclosed
WO-2006077425-A1 COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2005012256-A1 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2005-02-10 — — WO disclosed
Send feedback